Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes

Ji Young Park, Seung Woon Rha, Byoung Geol Choi, Jae Woong Choi, Sung Kee Ryu, Seunghwan Kim, Yung Kyun Noh, Se Yeon Choi, Raghavender Goud Akkala, Hu Li, Jabar Ali, Shaopeng Xu, Harris Abdullah Ngow, Jae Joong Lee, Gwang No Lee, Ji Bak Kim, Sunki Lee, Jin Oh Na, Cheol Ung Choi, Hong Euy LimJin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seogseo, Dong Joo Oh

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Background: High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10 mg or 20 mg) on the development of NODM up to three years in Asian patients. Methods: From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM(C-statistics: 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n = 409 patients) were enrolled for analysis. Results: Before PSM, the cumulative incidence of NODM(5.8% vs. 2.1%, p b 0.001),myocardial infarction (0.5% vs. 0.1%, p-value = 0.007), and major adverse cardio-cerebral event (MACCE, 1.8% vs. 0.7%, p-value = 0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9% vs. 3.2%, p = 0.064) in the LDA group, but the incidence of MACCE (1.2% vs. 1.5%, p-value = 1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR: 1.99, 95% CI: 1.00-3.98, p-value 0.050). Conclusions: In this study, the use of LDA tended to be a risk factor for NOD Min Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.

Original languageEnglish
Pages (from-to)502-506
Number of pages5
JournalInternational Journal of Cardiology
Issue number1
Publication statusPublished - 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Ireland Ltd. All rights reserved.


  • Atorvastatin
  • New onset diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes'. Together they form a unique fingerprint.

Cite this